• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>AstraZeneca PLC ADR

AstraZeneca PLC ADR

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. Amgen Ends Psoriasis-Drug Partnership With AstraZeneca -- Update

    Amgen Ends Psoriasis-Drug Partnership With AstraZeneca -- Update

  2. AstraZeneca to Invest $285 Million in Biological Medicines Plant in Sweden

    AstraZeneca to Invest $285 Million in Biological Medicines Plant in Sweden

  3. Amgen Ends Psoriasis-Drug Partnership With AstraZeneca

    Amgen Ends Psoriasis-Drug Partnership With AstraZeneca

  4. 4 Companies Leading the Next Wave of Cancer-Drug Innovation

    First movers and firms that provide combination therapies represent the best investment opportunities in the immuno-oncology market, says Morningstar's Damien Conover.

  5. Amgen to terminate participation in co-development and commercialization of brodalumab

    Amgen to terminate participation in co-development and commercialization of brodalumab

  6. FibroGen Announces Receipt of Milestone Payment from AstraZeneca for Successful Completion of Long-Term Pre-Clinical Safety Studies of Roxadustat

    FibroGen Announces Receipt of Milestone Payment from AstraZeneca for Successful Completion of Long-Term Pre-Clinical Safety Studies of Roxadustat

  7. Research and Markets: The Pharmaceutical Market: Sweden 2015

    Research and Markets: The Pharmaceutical Market: Sweden 2015

  8. Pennsylvania Bio Announces Chairman-Elect and New Board Members

    Pennsylvania Bio Announces Chairman-Elect and New Board Members

  9. Research and Markets: Japan Pharmaceutical Market Report 2015

    Research and Markets: Japan Pharmaceutical Market Report 2015

  10. Immune Pharmaceuticals Reports First Quarter 2015 Financial Results; Bertilimumab Phase II Trials Ready to Enroll Patients

    Immune Pharmaceuticals Reports First Quarter 2015 Financial Results; Bertilimumab Phase II Trials Ready to Enroll Patients

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.